EGFR and colorectal neoplasm: However if on the one hand we are now able to exclude from anti-EGFR treatment with monoclonal antibodies those patients with putative refractory colorectal tumors (i.e. those harboring a K-RAS mutation), on the other hand we are still incapable to accurately select responding patients among those without K-RAS mutations.